MedPath

A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices

Phase 3
Completed
Conditions
Schizophrenia and Schizoaffective Disorder
Registration Number
NCT00292409
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Brief Summary

The purpose of this clinical research study is to evaluate the overall effectiveness of 8 week of aripiprazole treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
400
Inclusion Criteria
  • diagnosis of schizophrenia or schizoaffective disorder being treated as outpatients,no response to past antipsychotic treatment and patients who symptoms are notoptimally controlled defined as CGI- S<7
Exclusion Criteria
  • pregnant or breastfeeding,patients at risk for committing suicide,diagnosis of mood disorders, delirium, dementia and other cognitive disorders,patients treatment resistant to otherantipyschotic medications and treatment with a long acting psychotic in which the last dose was within 3 months of treatment phase

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Clinical Global Impression-Improvement at endpoint
Secondary Outcome Measures
NameTimeMethod
Investigator's Assessment Questionnaire
Patient preference of medication at endpoint
Clinical Global Impression scale
© Copyright 2025. All Rights Reserved by MedPath